Clinic
Alegent Health Immanuel Medical Center
Alegent Health Immanuel Medical Center was paid $23.63M by Medicaid between Jan 2018 and Dec 2024, across 239 billing codes. Its largest line is 99283, emergency room visit (moderate) — 18% of everything it billed.
33Billing provider infoALEGENT HEALTH IMMANUEL MEDICAL CENTER
OMAHA, NE 68122
OMAHA, NE 68122
33aNPI1912085184assigned 11/02/2006
33bProvider typeAmbulatory Surgical Clinic/Center
28Total paid$23.63M
24GClaims659,424
24DCodes billed239
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Ambulatory Surgical Clinic/Center providers in Nebraska
Rank by total paid#2 of 35
Median peer was paid$190K
This provider vs. median124×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official KUIPER, EVERT controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 86,521 | $3.41M | |
| 2019 | 87,655 | $3.72M | |
| 2020 | 82,697 | $2.90M | |
| 2021 | 137,852 | $3.92M | |
| 2022 | 143,026 | $4.56M | |
| 2023 | 77,227 | $3.19M | |
| 2024incomplete | 44,446 | $1.94M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 18% | 32,990 | 30,627 | $4.35M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 17% | 27,724 | 25,058 | $4.02M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 9.4% | 14,617 | 12,841 | $2.22M |
| 96361 | Intravenous infusion, hydration; each additional hour | 6.1% | 8,321 | 5,930 | $1.45M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 5.3% | 24,413 | 6,822 | $1.26M |
| H2012 | Behavioral health day treatment, per hour | 5.0% | 6,963 | 939 | $1.17M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.6% | 3,172 | 2,914 | $841K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.5% | 9,039 | 8,589 | $838K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.8% | 3,833 | 3,432 | $661K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 2.7% | 5,976 | 5,527 | $636K |
| 97113 | 1.8% | 8,309 | 2,299 | $418K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 1.6% | 3,034 | 1,500 | $368K |
227 more codes
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | 1.4% | 1,006 | $341K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.3% | 1,035 | $315K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.3% | 3,968 | $314K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 1.0% | 4,477 | $245K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 975 | $234K |
| 59050 | <1% | 895 | $208K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 871 | $196K |
| 80050 | General health panel | <1% | 7,648 | $127K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 13,473 | $126K |
| G0378 | Hospital observation service, per hour | <1% | 3,975 | $121K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,458 | $111K |
| 90870 | <1% | 2,389 | $111K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 5,681 | $107K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,118 | $106K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 692 | $105K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 5,906 | $99K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 15,462 | $93K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 12,812 | $92K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 2,627 | $91K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,343 | $88K |
| 80053 | Comprehensive metabolic panel | <1% | 28,320 | $86K |
| 93971 | <1% | 733 | $82K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 533 | $78K |
| 97165 | <1% | 2,329 | $72K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 14,387 | $66K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 10,083 | $61K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 32,595 | $61K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,738 | $60K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 323 | $59K |
| 71045 | Radiologic examination, chest; single view | <1% | 9,170 | $57K |
| 76801 | <1% | 713 | $56K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 2,366 | $50K |
| 96376 | <1% | 5,028 | $48K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 18,761 | $47K |
| 97161 | <1% | 4,178 | $47K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 64 | $47K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 422 | $46K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 1,375 | $40K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 227 | $37K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,154 | $35K |
| 97116 | <1% | 2,593 | $32K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 265 | $31K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,141 | $31K |
| 84484 | <1% | 9,543 | $30K | |
| 81025 | <1% | 9,409 | $28K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 119 | $28K |
| 95811 | <1% | 51 | $27K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 5,379 | $27K |
| 70496 | <1% | 146 | $25K | |
| J3490 | Unclassified drugs | <1% | 42,185 | $24K |
| 83690 | <1% | 9,575 | $22K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 49 | $21K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 10,512 | $20K |
| 95886 | <1% | 89 | $20K | |
| 81001 | <1% | 11,919 | $20K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 1,102 | $20K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 154 | $19K |
| 73630 | <1% | 859 | $18K | |
| 80320 | <1% | 409 | $17K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 29 | $17K |
| 94760 | <1% | 3,790 | $17K | |
| 73610 | <1% | 769 | $17K | |
| 82962 | <1% | 12,185 | $17K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 844 | $16K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,914 | $15K |
| 72100 | <1% | 461 | $15K | |
| 97162 | <1% | 1,122 | $14K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 4,929 | $14K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 5,859 | $14K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 7,967 | $13K |
| 87040 | <1% | 2,756 | $13K | |
| J2704 | Injection, propofol, 10 mg | <1% | 4,775 | $12K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,109 | $12K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 3,597 | $12K |
| 83880 | <1% | 1,506 | $11K | |
| 83605 | <1% | 3,374 | $11K | |
| 73130 | <1% | 423 | $10K | |
| 84702 | <1% | 1,048 | $10K | |
| 80329 | <1% | 113 | $10K | |
| 85379 | <1% | 2,094 | $9K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 44 | $9K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 89 | $9K |
| 80061 | Lipid panel | <1% | 1,277 | $8K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,024 | $8K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 3,078 | $8K |
| 81003 | <1% | 8,475 | $8K | |
| 12001 | <1% | 30 | $8K | |
| 73564 | <1% | 237 | $7K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,092 | $7K |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 1,771 | $7K |
| 94060 | <1% | 128 | $7K | |
| 70486 | <1% | 73 | $7K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 4,221 | $7K |
| 73030 | <1% | 389 | $7K | |
| 95806 | <1% | 12 | $6K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,201 | $6K |
| 82728 | <1% | 904 | $6K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,445 | $6K |
| 71250 | <1% | 78 | $6K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,042 | $6K |
| 74019 | <1% | 121 | $5K | |
| 85610 | <1% | 2,644 | $5K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 40 | $5K |
| 90715 | <1% | 193 | $5K | |
| 94726 | <1% | 60 | $4K | |
| 86900 | <1% | 690 | $4K | |
| 12002 | <1% | 15 | $4K | |
| 72141 | <1% | 28 | $4K | |
| 87081 | <1% | 822 | $4K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 189 | $4K |
| 85730 | <1% | 1,572 | $4K | |
| 87210 | <1% | 1,226 | $4K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 850 | $4K |
| A9270 | Non-covered item or service | <1% | 19,244 | $4K |
| 94729 | <1% | 74 | $4K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 160 | $3K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 99 | $3K |
| 93017 | <1% | 18 | $3K | |
| 87186 | <1% | 907 | $3K | |
| 96367 | <1% | 333 | $3K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,709 | $3K |
| 74018 | <1% | 154 | $3K | |
| 76770 | <1% | 16 | $3K | |
| 87077 | <1% | 1,141 | $3K | |
| 86850 | <1% | 228 | $2K | |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 81 | $2K |
| 83550 | <1% | 621 | $2K | |
| 87420 | <1% | 101 | $2K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 323 | $2K |
| 83540 | <1% | 761 | $2K | |
| G0515 | Development of cognitive skills to improve attention, memory, problem solving (includes compensatory training), direct (one-on-one) patient contact, each 15 minutes | <1% | 64 | $2K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,130 | $2K |
| 82607 | <1% | 261 | $2K | |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 19,369 | $2K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 20 | $2K |
| 73110 | <1% | 101 | $2K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 28 | $2K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,256 | $2K |
| 71271 | <1% | 17 | $2K | |
| 76642 | <1% | 18 | $2K | |
| A4649 | Surgical supply; miscellaneous | <1% | 393 | $2K |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 829 | $2K |
| 83735 | <1% | 1,878 | $2K | |
| 76536 | <1% | 12 | $2K | |
| 97542 | <1% | 25 | $2K | |
| 84439 | <1% | 163 | $1K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 247 | $1K |
| 85027 | <1% | 627 | $1K | |
| 87147 | <1% | 156 | $1K | |
| 86901 | <1% | 661 | $1K | |
| 77080 | <1% | 27 | $1K | |
| 97750 | <1% | 74 | $1K | |
| 0099U | <1% | 14 | $1K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 421 | $1K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 3,914 | $1K |
| 73502 | <1% | 97 | $1K | |
| 72040 | <1% | 26 | $895.20 | |
| 70498 | <1% | 49 | $838.98 | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 12 | $824.99 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 2,180 | $816.43 |
| 97035 | <1% | 101 | $733.39 | |
| 85018 | <1% | 524 | $718.92 | |
| 80164 | <1% | 123 | $714.47 | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 12 | $712.59 |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 192 | $584.52 |
| 87205 | <1% | 405 | $554.64 | |
| 73140 | <1% | 16 | $542.22 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 478 | $540.48 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 509 | $465.87 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 930 | $448.89 |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 513 | $384.30 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 726 | $348.15 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 107 | $334.98 |
| 86140 | <1% | 192 | $275.59 | |
| 82077 | <1% | 3,258 | $252.91 | |
| 99152 | <1% | 43 | $235.17 | |
| 84703 | <1% | 228 | $227.41 | |
| 80178 | <1% | 29 | $202.12 | |
| 85652 | <1% | 141 | $197.47 | |
| 84100 | <1% | 761 | $152.53 | |
| 84145 | <1% | 332 | $148.26 | |
| 80069 | <1% | 171 | $122.80 | |
| 80143 | <1% | 1,272 | $122.58 | |
| 82550 | <1% | 52 | $93.68 | |
| 82247 | <1% | 15 | $87.22 | |
| 82784 | <1% | 14 | $81.48 | |
| 80179 | <1% | 1,250 | $79.96 | |
| 99153 | Mod sedat endo service >5yrs | <1% | 15 | $65.04 |
| 87070 | <1% | 90 | $53.73 | |
| J7510 | Prednisolone oral, per 5 mg | <1% | 68 | $44.53 |
| 90686 | <1% | 12 | $40.65 | |
| G8990 | Other physical or occupational therapy primary functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 660 | $39.90 |
| 87428 | <1% | 14 | $23.67 | |
| 82803 | <1% | 55 | $13.31 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 183 | $8.70 |
| G0008 | Administration of influenza virus vaccine | <1% | 12 | $1.60 |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | <1% | 23 | $1.38 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,611 | $0.36 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 602 | $0.01 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 0% | 511 | $0.00 |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 230 | $0.00 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 57 | $0.00 |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 255 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 122 | $0.00 |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 603 | $0.00 |
| Q9957 | Injection, perflutren lipid microspheres, per ml | 0% | 26 | $0.00 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 76 | $0.00 |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 0% | 14 | $0.00 |
| 85014 | 0% | 37 | $0.00 | |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 59 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 16 | $0.00 |
| 73562 | 0% | 15 | $0.00 | |
| G8992 | Other physical or occupational therapy primary functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 279 | $0.00 |
| J3411 | Injection, thiamine hcl, 100 mg | 0% | 110 | $0.00 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 59 | $0.00 |
| J1815 | Injection, insulin, per 5 units | 0% | 348 | $0.00 |
| G8991 | Other physical or occupational therapy primary functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 799 | $0.00 |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 175 | $0.00 |
| 76830 | Ultrasound, transvaginal | 0% | 62 | $0.00 |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 84 | $0.00 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 0% | 134 | $0.00 |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 364 | $0.00 |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 168 | $0.00 |
| C1769 | Guide wire | 0% | 32 | $0.00 |
| 94761 | 0% | 32 | $0.00 | |
| 76377 | 0% | 15 | $0.00 | |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 40 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialKUIPER, EVERT (CEO - CHI HEALTH)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.